Navigation Links
Scientists perform 'tricky' operation

Trichomonas vaginalis colonises the urogenital tract and causes the infection also known as "trick", the most common non-viral STI.

University of Queensland PhD scholar Rebecca Dunne was one of a team of 65 scientists that worked on the project to sequence the genome, which could offer clues to better treatments for both men and women.

Ms Dunne said the results would allow researchers to hone in on genes and gene families of interest, particularly those involved in drug resistance.

"The completion of the genome sequence by The Institute for Genomic Research (TIGR) and subsequent annotation of the genome database has opened many avenues of research by providing a searchable data set," Ms Dunne said.

"Drug resistance in many human pathogens is increasing. T. vaginalis is among these, with no alternative drugs approved to treat resistant infections.

"This is particularly an issue in developing countries, where the number of infected individuals is high and the access to public health services is low.

"Now that researchers have access to a complete genome dataset the search for alternative drug targets can really take-off."

Amazingly, the pesky parasite was found to have an exceptionally large collection of DNA, with the possibility of having more genes than humans.

But Ms Dunne said while the sequencing of the genome project has largely elevated awareness of T. vaginalis among researchers, public awareness remains low, especially in developing countries where it has the most impact.

"This is a problem as infection with T. vaginalis increases the transmission and acquisition of many other serious STIs, including HIV.

"Furthermore, prolonged infection with T. vaginalis associates with pre-term birth, low infant birth weight and some cervical cancers.

"Alarmingly, trichomoniasis is not considered a notifiable disease."

Routine gynaecological check-ups do n ot test for this particular STI and the infection does not require public health notification.

Because of this, and also due to the broad and non-specific nature of symptoms, which can range from severe to negligible depending on the individual, some people pass it on without knowing.

"Furthermore, the non-specific nature (or in some cases, absence) of trichomoniasis symptoms often confuses it with other STIs, making the process of diagnosis itself, difficult," Ms Dunne said.

"Many infections remain undiagnosed as a result."

It is hoped that the results of the project will help research and improve treatments, in turn sponsoring awareness.

Ms Dunne's contribution to the project involved the identification and annotation of several large families of genes related to those involved in various mechanisms of antimicrobial resistance.

As a result of the genome being sequenced, she has since been able to localise specific genes of interest to the whole chromosome and begin the mapping process.

"Mapping the genome is the next step in the genome sequencing of T. vaginalis and will create a visual blueprint of the parasite, allowing researchers to see where their genes fit in to the big picture."

The results of the collaborative project have been published in the prestigious international journal
'"/>

Source:Research Australia


Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... February 17, 2017 According ... by Product (Consumables, Service), Type (Safety, Efficacy, Validation), ... Drug Discovery and Development, Disease-Risk) - Global Forecast ... projected to reach USD 53.34 Billion by 2021 ... a CAGR of 13.8% during the forecast period ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... and GREENWICH, Conn. ... private investment firm focused on venture growth investments ... promotion of Josh Richardson , M.D. to ... investments in biotechnology companies.  He is a board ... important roles in Longitude,s investments in Aimmune Therapeutics, ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
Breaking Biology Technology: